MGMT and glioblastoma: To assess the impact of TTFields on the procoagulant activity of tumor cells, we quantified surface TF levels and conducted transcriptomic analysis on four patient-derived GBM cell lines: two with unmethylated MGMT promoter status (HROG04, GBM15) and two with methylated MGMT (HROG13, GBM06) (Fig. 4).